The results show the role of cell–cell interaction and intracellular NRF2-YAP signaling pathway in determining ferroptosis and show that malignant mutations in the NRF2-YAP signaling pathway can predict the response of cancer cells to future induction therapy for ferroptosis [72]. This evidence concerns the gene NFE2L2 and cancer.